Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for INM.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2006. Start Trial.
Date Value
March 31, 2026 -1.759M
December 31, 2025 -2.352M
September 30, 2025 -1.608M
June 30, 2025 -1.992M
March 31, 2025 -1.562M
December 31, 2024 -2.448M
September 30, 2024 -1.827M
June 30, 2024 -0.9629M
March 31, 2024 -1.964M
December 31, 2023 -1.817M
September 30, 2023 -2.174M
June 30, 2023 -0.7367M
March 31, 2023 -1.655M
December 31, 2022 -2.618M
September 30, 2022 -2.256M
June 30, 2022 -3.989M
March 31, 2022 -5.274M
December 31, 2021 -3.532M
September 30, 2021 -2.654M
June 30, 2021 -2.198M
March 31, 2021 -5.598M
December 31, 2020 -1.063M
September 30, 2020 -1.372M
June 30, 2020 -1.244M
March 31, 2020 -1.471M
Date Value
December 31, 2019 -2.066M
September 30, 2019 -2.365M
June 30, 2019 -1.768M
March 31, 2019 -2.077M
December 31, 2018 -1.391M
September 30, 2018 -1.317M
June 30, 2018 -1.006M
March 31, 2018 -0.7516M
December 31, 2017 -0.7844M
September 30, 2017 -1.077M
June 30, 2017 -0.7351M
March 31, 2017 -0.7428M
December 31, 2016 -0.6437M
September 30, 2016 -0.1663M
June 30, 2016 -0.1126M
March 31, 2016 -0.0349M
December 31, 2015 -0.1092M
September 30, 2015 -0.1307M
June 30, 2015 -0.7565M
March 31, 2015 -0.6728M
December 31, 2014 -0.0881M
September 30, 2014 -0.1053M
June 30, 2014 -0.6248M
March 31, 2014 0.0006M
December 31, 2013 -0.0005M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
NervGen Pharma Corp. -4.086M
Milestone Pharmaceuticals, Inc. -22.53M
Clearmind Medicine, Inc. -1.792M
Lexaria Bioscience Corp. -1.635M
Target Group, Inc. (Canada) -0.2229M